Pretreatment characteristics
| . | SAA . | VSAA . |
|---|---|---|
| Registered | 86 | 119 |
| Evaluable | 84 | 117 |
| Sex (M/F) | 48/36 | 65/52 |
| Median age, y (range) | 8 (0-17) | 9 (0-15) |
| Cause of AA | ||
| Idiopathic | 73 | 91 |
| Hepatitis | 8 | 24 |
| Viral infection | 1 | 2 |
| Drug | 2 | 0 |
| Median days from diagnosis to treatment (range) | 13 (1-94) | 19 (1-179) |
| . | SAA . | VSAA . |
|---|---|---|
| Registered | 86 | 119 |
| Evaluable | 84 | 117 |
| Sex (M/F) | 48/36 | 65/52 |
| Median age, y (range) | 8 (0-17) | 9 (0-15) |
| Cause of AA | ||
| Idiopathic | 73 | 91 |
| Hepatitis | 8 | 24 |
| Viral infection | 1 | 2 |
| Drug | 2 | 0 |
| Median days from diagnosis to treatment (range) | 13 (1-94) | 19 (1-179) |
SAA indicates severe aplastic anemia; VSAA, very severe aplastic anemia